Welcome to the BioPharma Revolution: 60 Minutes on the Intersection of Science, Business, Policy, and the Law

March 21, 2023 9:00am

Julie Wu
Supervisory Patent Examiner, Immunotherapy and Recombinant Antibodies

Catherine A. Brandon
Arnold & Porter Kaye Scholer LLP

Rebecca K. Wood
Sidley Austin LLP
(Former Chief Counsel, FDA)

In this opening session, panelists will provide an overview of the driving force behind the BioPharma revolution and explain the opportunities it offers by detailing the design and delivery of new medicines and therapies, including gene therapy, cell therapy, CAR-T, and bispecific and RNA treatments.

  • Understanding how mRNA, CRISPR, and CAR-T are game changers from scientific, commercial, legal, and policy perspectives
  • Analyzing the impact of the Inflation Reduction Act (IRA) on BioPharma innovation, patent protection and market entry
    • How will the IRA impact the ability to secure investments, partnerships, and acquisitions?
  • How will the Biden EO support industry, R&D, and workforce development?
  • How are these therapies changing the way we look at treatment and prevention?
    • Where do they fit into the existing landscape of small and large molecules